journal
https://read.qxmd.com/read/38553264/evaluation-of-uro17%C3%A2-to-improve-non-invasive-detection-of-bladder-cancer
#21
JOURNAL ARTICLE
Sima P Porten, Elizabeth Y Wang, Poonam Vohra, Peter R Carroll, Sholeh Jahanfard, Nam W Kim
BACKGROUND: The gold standard for detecting bladder cancer is cystoscopy with biopsy or transurethral resection confirming histologic diagnosis. URO17® employs a chromogenically labeled monoclonal antibody to keratin 17 (k17), an intermediate filament cytoskeleton molecule associated with bladder, pancreatic, and cervical cancers. Preliminary studies evaluating k17 demonstrated a high sensitivity and specificity for the detection of bladder cancer, supporting the need for further study...
March 28, 2024: Urologic Oncology
https://read.qxmd.com/read/38522976/nomogram-for-personalized-prognostic-assessment-of-children-with-favorable-histology-wilms-tumor-a-retrospective-analysis
#22
JOURNAL ARTICLE
Zihong Wang, Jiayi Li, Pei Liu, Xianghui Xie, Hongcheng Song, Weiping Zhang
OBJECTIVE: This retrospective study aimed to construct and validate a nomogram for personalized prognostic assessment of favorable histology Wilms tumor (FHWT) based on clinical and pathological variables. METHODS AND MATERIALS: This was a retrospective study collected data from patients who underwent surgery for FHWT between March 2007 and November 2022 at Beijing Children's Hospital. Univariate and multivariate Cox proportional hazards regression analyses were conducted to determine the significance variables and constructed the nomogram in predicting event-free survival (EFS) in FHWT patients...
March 23, 2024: Urologic Oncology
https://read.qxmd.com/read/38522975/testing-the-external-validity-of-the-pout-iii-trial-adjuvant-platnium-based-chemotherapy-in-upper-tract-urothelial-carcinoma-in-a-north-american-cohort
#23
JOURNAL ARTICLE
Nicholas James Corsi, Alex Stephens, Marco Finati, Taylor Malchow, Chase Morrison, Matthew Davis, Keinnan Hares, Matthew P Corsi, Sohrab Arora, Giuseppe Chiarelli, Giuseppe Ottone Cirulli, Riccardo Autorino, Akshay Sood, Craig Rogers, Firas Abdollah
OBJECTIVE: The European POUT III randomized controlled trial provided level-one evidence that adjuvant platinum-based chemotherapy is the standard of care following nephroureterectomy (RNU) for locally invasive or node-positive upper tract urothelial carcinoma. We aim to assess this European randomized controlled trial's generalizability (external validity) to a North American cohort, using a nationwide database. MATERIALS AND METHODS: To compare trial patients with those seen in real-world practice, we simulated the trial inclusion criteria using data from the National Cancer Database (NCDB)...
March 23, 2024: Urologic Oncology
https://read.qxmd.com/read/38519377/the-new-who-category-of-molecularly-defined-renal-carcinomas-clinical-and-diagnostic-features-and-management-implications
#24
REVIEW
Jonathan Kanakaraj, Justin Chang, Lance J Hampton, Steven Christopher Smith
The evolution of classification of renal tumors has been impacted since the turn of the millennium by rapid progress in histopathology, immunohistochemistry, and molecular genetics. Together, these features have enabled firm recognition of specific, classic types of renal cell carcinomas, such as clear cell renal cell carcinoma, that in current practice trigger histologic-type specific management and treatment protocols. Now, the fifth Edition World Health Classification's new category of "Molecularly defined renal carcinomas" changes the paradigm, defining a total of seven entities based specifically on their fundamental molecular underpinnings...
March 21, 2024: Urologic Oncology
https://read.qxmd.com/read/38514276/hospital-and-departmental-level-strategies-for-managing-the-impact-of-adverse-events-on-surgeons
#25
REVIEW
Gemma Scrimgeour, Kevin Turner
Adverse events have a profound impact on surgeons. This impact extends to physical and mental health, psychological wellbeing, and professional performance. Surgeons are ill prepared for these consequences of adverse events and are under-supported when they inevitably occur. Here we review the data on how adverse events affect surgeons. We explore the efforts made to date to both prepare surgeons before and support them after such events and we make recommendations regarding how this should and could be done better...
March 20, 2024: Urologic Oncology
https://read.qxmd.com/read/38508941/the-assessment-of-bladder-cancer-resectability-with-bimanual-palpation-a-prospective-study-in-laparoscopy-and-open-cystectomy-patients
#26
JOURNAL ARTICLE
Anna K Czech, Katarzyna Gronostaj, Jakub Frydrych, Kamil Polok, Jakub Fronczek, Przemyslaw Dudek, Lukasz Belch, Marcin Chlosta, Dominik Choragwicki, Tomasz Dymowski, Mateusz Ostachowski, Katarzyna Piatek-Koziej, Mikołaj Przydacz, Pawel Pyrkosz, Tomasz Wiatr, Marcin Wrozek, Piotr L Chlosta
PURPOSE: To evaluate the value of examination under anesthesia (EUA) in the assessment of bladder resectability during cystectomy. MATERIALS AND METHODS: This prospective study included consecutive patients undergoing cystectomy for bladder cancer at a single center between June 2017 and October 2020. EUA was conducted before cystectomy by two urologists who assessed the bladder for limited mobility. One examiner was blinded to the imaging results. Soft tissue surgical margin status in the pathological evaluation of a cystectomy specimen served as a measure of resectability...
March 19, 2024: Urologic Oncology
https://read.qxmd.com/read/38508940/prostatic-adenocarcinoma-molecular-underpinnings-and-treatment-related-options
#27
REVIEW
Divyangi Paralkar, Amir Akbari, Manju Aron
Prostate cancer is heterogeneous with varied pathologic features and presents with a wide spectrum of clinical manifestations from indolent to advanced cancer. Interrogation of the molecular landscape of prostate cancer has unveiled the complex genomic alterations in these tumors, which significantly impacts tumor biology. The documented array of chromosomal alterations, gene fusions, and epigenetic changes not only play a crucial role in oncogenesis and disease progression, but also impacts response and resistance to various therapeutic modalities...
March 19, 2024: Urologic Oncology
https://read.qxmd.com/read/38503592/real-world-use-dose-intensity-and-adherence-to-enfortumab-vedotin-in-locally-advanced-or-metastatic-urothelial-cancer
#28
JOURNAL ARTICLE
Ronac Mamtani, Konstantinos Tsingas, Ravi B Parikh, Dina Elsouda, Lisa Mucha, Rupali Fuldeore, Rebecca A Hubbard
BACKGROUND: Enfortumab vedotin (EV) monotherapy is approved for the treatment of advanced urothelial cancer as later-line therapy (post-immunotherapy and -platinum-chemotherapy) and as earlier-line therapy (cisplatin-ineligible, at least 1 prior therapy). We examined real-world EV monotherapy use, dose intensity and adherence across 280 US cancer clinics. METHODS: This postmarketing study used data from a nationwide (United States) deidentified patient-level electronic health record-derived database...
March 18, 2024: Urologic Oncology
https://read.qxmd.com/read/38503591/genitourinary-toxicity-in-patients-receiving-turp-prior-to-hypofractionated-radiotherapy-for-clinically-localized-prostate-cancer-a-scoping-review
#29
REVIEW
Thomas Neerhut, Richard Grills, Rod Lynch, Patrick Daniel Preece, Kathryn McLeod
BACKGROUND: When compared with conventional external beam radiotherapy, hypofractionated radiotherapy has led to less treatment sessions and improved quality of life without compromising oncological outcomes for men with prostate cancer. Evidence has shown transurethral prostatic resection prior to brachytherapy and external beam radiotherapy is associated with worsening genitourinary toxicity. However, there is no review of genitourinary toxicity when TURP occurs prior to definitive hypofractionated radiotherapy...
March 18, 2024: Urologic Oncology
https://read.qxmd.com/read/38490923/contemporary-risk-of-biochemical-recurrence-after-radical-prostatectomy-in-the-active-surveillance-era
#30
JOURNAL ARTICLE
Sanjay Das, Michael Luu, Martha Terris, Zachary Klaassen, Christopher J Kane, Christopher Amling, Matthew Cooperberg, Lourdes Guerrios Rivera, William Aronson, Stephen J Freedland, Timothy J Daskivich
OBJECTIVES: To assess whether contemporary risks of biochemical recurrence (BCR) after radical prostatectomy (RP) in the AS era differ from historical estimates due to changes in tumor risk case mix and improvements in risk stratification. MATERIALS AND METHODS: We sampled 6,682 men who underwent RP for clinically localized disease between 2000 and 2017 from the VA SEARCH database. Kaplan Meier analysis was used to calculate incidence of BCR before and after 2010 overall and within tumor risk subgroups...
March 14, 2024: Urologic Oncology
https://read.qxmd.com/read/38485644/ductal-intraductal-and-cribriform-carcinoma-of-the-prostate-molecular-characteristics-and-clinical-management
#31
REVIEW
Yibo Shi, Hanzhang Wang, Borivoj Golijanin, Ali Amin, Joanne Lee, Mark Sikov, Elias Hyams, Gyan Pareek, Benedito A Carneiro, Anthony E Mega, Galina G Lagos, Lisha Wang, Zhiping Wang, Liang Cheng
Prostatic acinar adenocarcinoma accounts for approximately 95% of prostate cancer (CaP) cases. The remaining 5% of histologic subtypes of CaP are known to be more aggressive and have recently garnered substantial attention. These histologic subtypes - namely, prostatic ductal adenocarcinoma (PDA), intraductal carcinoma of the prostate (IDC-P), and cribriform carcinoma of the prostate (CC-P) - typically exhibit distinct growth characteristics, genomic features, and unique oncologic outcomes. For example, PTEN mutations, which cause uncontrolled cell growth, are frequently present in IDC-P and CC-P...
March 13, 2024: Urologic Oncology
https://read.qxmd.com/read/38480079/alignment-of-molecular-subtypes-across-multiple-bladder-cancer-subtyping-classifiers
#32
JOURNAL ARTICLE
Moritz J Reike, Joep J de Jong, Tarek A Bismar, Stephen A Boorjian, Omar Y Mian, Jonathan L Wright, Marc A Dall'Era, Hristros Z Kaimakliotis, Yair Lotan, Joost L Boormans, Peter C Black, Ewan A Gibb
BACKGROUND: Treatment of patients with muscle-invasive bladder cancer (MIBC) includes cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC). Molecular subtypes have been associated with patient outcomes after NAC and RC, but the reported results have been highly inconsistent. OBJECTIVE: To evaluate the association of molecular subtypes from different classifiers with overall survival (OS) among patients with MIBC who underwent RC. MATERIALS AND METHODS: We analyzed gene expression data generated from transurethral resection of MIBC from a previously assembled and published meta-cohort, NACmeta (N = 601, 247 treated with NAC+RC and 354 RC without NAC), where extended follow-up was available...
March 12, 2024: Urologic Oncology
https://read.qxmd.com/read/38480078/efficacy-of-cytoreductive-radical-cystectomy-in-metastatic-urothelial-bladder-cancer-based-on-site-and-number-of-metastases
#33
JOURNAL ARTICLE
Vincent E Xu, Ryan M Antar, Luca Bertozzi, Arthur Drouaud, Sarah Azari, Sean M Lee, Michael J Whalen
BACKGROUND: Recent studies have highlighted the overall survival (OS) benefit of cytoreductive radical cystectomy (CRC) in metastatic bladder cancer (mBCa). Cytoreductive surgery has been established in other urologic cancers. However, the efficacy of CRC and optimal criteria for patient selection in mBCa is unclear. This study investigated the oncologic efficacy of CRC, particularly emphasizing the location and number of metastasis sites as a predictor of survival and treatment response...
March 12, 2024: Urologic Oncology
https://read.qxmd.com/read/38480077/different-diagnostic-strategies-combining-prostate-health-index-and-magnetic-resonance-imaging-for-predicting-prostate-cancer-a-multicentre-study
#34
JOURNAL ARTICLE
Meikai Zhu, Qiang Fu, Yunjiang Zang, Zhiqiang Shao, Yongheng Zhou, Zhiwen Jiang, Wenfu Wang, Benkang Shi, Shouzhen Chen, Yaofeng Zhu
OBJECTIVE: To explore how prostate health index (PHI) and multiparametric magnetic resonance imaging (mpMRI) should be used in concert to improve diagnostic capacity for clinically significant prostate cancers (CsCaP) in patients with prostate-specific antigen (PSA) between 4 and 20 ng/ml. METHODS: About 426 patients fulfilling the inclusion criteria were included in this study. Univariable and multivariable logistic analyses were performed to analyze the association between the clinical indicators and CaP/CsCaP...
March 12, 2024: Urologic Oncology
https://read.qxmd.com/read/38443238/the-prognostic-role-of-histomorphological-subtyping-in-nonmetastatic-papillary-renal-cell-carcinoma-after-curative-surgery-is-subtype-really-irrelevant-a-propensity-score-matching-analysis-of-a-multi-institutional-real-life-data
#35
JOURNAL ARTICLE
Selcuk Erdem, Riccardo Bertolo, Riccardo Campi, Umberto Capitanio, Daniele Amparore, Umberto Anceschi, Maria Carme Mir, Eduard Roussel, Nicola Pavan, Umberto Carbonara, Onder Kara, Tobias Klatte, Michele Marchioni, Angela Pecoraro, Stijn Muselaers, Laura Marandino, Pietro Diana, Leonardo Borregales, Carlotta Palumbo, Hannah Warren, Zhenjie Wu, Anna Calio, Chiara Ciccarese, Enes Degirmenci, Resat Aydin, Giacomo Rebez, Luigi Schips, Giuseppe Simone, Andrea Minervini, Sergio Serni, Faruk Ozcan
BACKGROUND AND AIM: The role of histomorphological subtyping is an issue of debate in papillary renal cell carcinoma (papRCC). This multi-institutional study investigated the prognostic role of histomorphological subtyping in patients undergoing curative surgery for nonmetastatic papRCC. PATIENTS AND METHODS: A total of 1,086 patients undergoing curative surgery were included from a retrospectively collected multi-institutional nonmetastatic papRCC database. The patients were divided into 2 groups based on histomorphological subtyping (type 1, n = 669 and type 2, n = 417)...
March 4, 2024: Urologic Oncology
https://read.qxmd.com/read/38433022/comparative-analysis-of-prognosis-and-gene-expression-in-prostate-cancer-patients-with-site-specific-visceral-metastases
#36
JOURNAL ARTICLE
Peng Zhang, Tieding Chen, Ming Yang
INTRODUCTION: Prostate cancer patients with visceral metastases often exhibited poor prognoses. Few researches had compared the prognostic impact and gene expression profiles among distinct visceral metastatic sites. Therefore, we conducted a comprehensive study utilizing data from the Surveillance, Epidemiology, and End Results (SEER) database and the Gene Expression Omnibus database. PATIENTS AND METHODS: We analyzed the prostate cancer-specific mortality (PCSM) risk for 8,170 patients diagnosed with metastatic prostate cancer (mPCa) between 2000 and 2019, utilizing data from the SEER 17 registry database...
March 2, 2024: Urologic Oncology
https://read.qxmd.com/read/38431487/performance-of-standard-systematic-biopsy-versus-mri-trus-fusion-biopsy-using-the-navigo%C3%A2-system-in-contemporary-cohort
#37
JOURNAL ARTICLE
Omri Nativ, Alexander Shefler, Jacob Bejar, Solomon Peschansky, Arnon Lavi, Cohen Michael, Ofer Nativ
INTRODUCTION: The introduction of multi parameter magnetic resonance imaging (mpMRI) of the prostate in combination with MRI/TRUS fusion and systematic biopsy resulted in improved detection of prostate cancer. The aim of the current study was to document the performance of MRI/TRUS fusion biopsy of the prostate using the Navigo™ software in a contemporary cohort of patients from nonreferral centers. MATERIAL AND METHODS: We performed a two centers prospective data collection (2014-2020) for men with clinically suspected Pca and patients on active surveillance for low-risk Pca that were referred for TRUS biopsy after performing mpMRI of the prostate with a visible lesion...
March 1, 2024: Urologic Oncology
https://read.qxmd.com/read/38429124/the-role-of-neoadjuvant-chemotherapy-for-patients-with-variant-histology-muscle-invasive-bladder-cancer-undergoing-robotic-cystectomy-data-from-the-international-robotic-cystectomy-consortium
#38
JOURNAL ARTICLE
Ian Cooke, Nassib Abou Heidar, Abdul Wasay Mahmood, Ali Ahmad, Zhe Jing, Michael Stöckle, Andrew A Wagner, Morgan Roupret, Eric Kim, Nikhil Vasdev, Derya Balbay, Koon Ho Rha, Ahmed Aboumohamed, Prokar Dasgupta, Thomas J Maatman, Lee Richstone, Peter Wiklund, Franco Gaboardi, Qiang Li, Ahmed A Hussein, Khurshid Guru
OBJECTIVE: To assess the role of neoadjuvant chemotherapy (NAC) before robot-assisted radical cystectomy (RARC) for patients with variant histology (VH) muscle-invasive bladder cancer (MIBC). METHODS: Retrospective review of 988 patients who underwent RARC (2004-2023) for MIBC. Primary outcomes included the utilization of NAC among this cohort of patients, frequency of downstaging, and discordance between preoperative and final pathology in terms of the presence of VH...
February 29, 2024: Urologic Oncology
https://read.qxmd.com/read/38423852/development-of-a-microultrasound-based-nomogram-to-predict-extra-prostatic-extension-in-patients-with-prostate-cancer-undergoing-robot-assisted-radical-prostatectomy
#39
JOURNAL ARTICLE
Nicola Frego, Roberto Contieri, Vittorio Fasulo, Davide Maffei, Pier Paolo Avolio, Paola Arena, Edoardo Beatrici, Federica Sordelli, Fabio De Carne, Massimo Lazzeri, Alberto Saita, Rodolfo Hurle, Nicolò Maria Buffi, Paolo Casale, Giovanni Lughezzani
OBJECTIVES: To develop a microultrasound-based nomogram including clinicopathological parameters and microultrasound findings to predict the presence of extra-prostatic extension and guide the grade of nerve-sparing. MATERIAL AND METHODS: All patients underwent microultrasound the day before robot-assisted radical prostatectomy. Variables significantly associated with extra-prostatic extension at univariable analysis were used to build the multivariable logistic model, and the regression coefficients were used to develop the nomogram...
February 28, 2024: Urologic Oncology
https://read.qxmd.com/read/38418270/survivin-as-a-potential-biomarker-in-the-diagnosis-of-bladder-cancer-a-systematic-review-and-meta-analysis
#40
REVIEW
Zhiren Zhou, Lina Zou, Yue Guan, Lizhe Jiang, Yanan Liu, Xueqing Zhang, Xiaojing Huang, Huanyu Ren, Zheng Li, Huiru Niu, Hao Liao, Xiaojing Zhang, Hongzhi Pan, Shengzhong Rong, Hongkun Ma
Early detection, diagnosis, and treatment take on critical significance in preventing and treating bladder cancer. As indicated by numerous studies, survivin can serve as a biomarker of bladder cancer, whereas the results of a wide variety of studies have been controversial. This paper is to assess the accuracy of survivin in the diagnosis of bladder cancer by a meta-analysis. The studies regarding the diagnosis of bladder cancer using survivin were systematically retrieved from the CNKI, WanFang, CBM, VIP, Web of science, cochrane library and pubmed were extracted, and the literature quality was assessed...
February 27, 2024: Urologic Oncology
journal
journal
32958
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.